Status: Recruiting
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
Participants needed: 564
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: AstraZenecaUpdated: Jun 23, 2026Locations: 14
Eligibility criteria
Female participants only, aged 18 or above [+4]
Any cytotoxic chemotherapy, investigational agents, or other anti-cancer drugs f... [+16]